Search Results 101-110 of 18688 for amyloidosis
AL amyloidosis patients with AL amyloidosis have not been treated with any systemic therapy, or AL amyloidosis clinically overt multiple myeloma; i.e. ...
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, ...
Cardiac amyloidosis occurs when a protein byproduct called amyloid builds up in the heart muscle. This inhibits the hearts ability to pump blood in is sometimes ...
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with ...
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (ConTTRibute). Print details. Share ...
Discovery's Edge: Cell research on amyloidosis featured image. Research. Discovery's Edge: Cell research on amyloidosis. Mayo Clinic Staff. March 21, 2017.
The amyloidoses are a group of protein misfolding diseases characterized by the accumulation of insoluble amyloid fibrils that lead to cell death and tissue ...
The purpose of this study is to evaluate the effectiveness and safety of patisiran in participants with Transthyretin Amyloidosis With Cardiomyopathy.
A Study Using Magnetic Resonance Elastography to Assess Heart Muscle Stiffness in Patients with Cardiac Amyloidosis · Share · Facebook · Twitter.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!